Kent Hutchison
Concepts (550)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 65 | 2023 | 838 | 9.680 |
Why?
| | Alcohol Drinking | 48 | 2024 | 858 | 6.530 |
Why?
| | Cues | 38 | 2018 | 329 | 4.820 |
Why?
| | Brain | 56 | 2026 | 3009 | 4.730 |
Why?
| | Cannabis | 22 | 2026 | 518 | 4.110 |
Why?
| | Cannabidiol | 12 | 2025 | 142 | 3.980 |
Why?
| | Dronabinol | 17 | 2025 | 251 | 3.890 |
Why?
| | Ethanol | 31 | 2021 | 634 | 3.570 |
Why?
| | Alcohol-Related Disorders | 17 | 2021 | 126 | 3.490 |
Why?
| | Magnetic Resonance Imaging | 61 | 2026 | 3980 | 2.940 |
Why?
| | Tobacco Use Disorder | 15 | 2021 | 217 | 2.870 |
Why?
| | Smoking | 30 | 2019 | 1483 | 2.650 |
Why?
| | Marijuana Abuse | 16 | 2024 | 215 | 2.640 |
Why?
| | Hallucinogens | 6 | 2026 | 112 | 2.600 |
Why?
| | Cannabinoids | 9 | 2026 | 184 | 2.540 |
Why?
| | Marijuana Use | 8 | 2025 | 222 | 2.390 |
Why?
| | Substance-Related Disorders | 19 | 2023 | 1112 | 2.250 |
Why?
| | Receptors, Dopamine D2 | 10 | 2018 | 93 | 2.120 |
Why?
| | Behavior, Addictive | 14 | 2021 | 89 | 2.060 |
Why?
| | Adult | 141 | 2026 | 41405 | 1.970 |
Why?
| | Gray Matter | 7 | 2023 | 97 | 1.930 |
Why?
| | Nerve Net | 10 | 2023 | 288 | 1.780 |
Why?
| | Brain Mapping | 14 | 2023 | 550 | 1.710 |
Why?
| | Reward | 11 | 2018 | 248 | 1.680 |
Why?
| | Polymorphism, Genetic | 14 | 2012 | 615 | 1.660 |
Why?
| | Varenicline | 4 | 2017 | 28 | 1.630 |
Why?
| | Neuroimaging | 10 | 2026 | 309 | 1.560 |
Why?
| | Marijuana Smoking | 7 | 2021 | 249 | 1.550 |
Why?
| | Receptors, Dopamine D4 | 11 | 2011 | 27 | 1.520 |
Why?
| | Young Adult | 62 | 2026 | 14437 | 1.490 |
Why?
| | Male | 152 | 2026 | 73950 | 1.470 |
Why?
| | Substance Withdrawal Syndrome | 13 | 2019 | 185 | 1.420 |
Why?
| | Female | 154 | 2026 | 80076 | 1.420 |
Why?
| | Genotype | 24 | 2014 | 1875 | 1.410 |
Why?
| | Naltrexone | 12 | 2019 | 115 | 1.390 |
Why?
| | Executive Function | 5 | 2020 | 472 | 1.380 |
Why?
| | Humans | 203 | 2026 | 147293 | 1.360 |
Why?
| | Flowers | 4 | 2024 | 61 | 1.340 |
Why?
| | White Matter | 3 | 2021 | 170 | 1.320 |
Why?
| | Mindfulness | 2 | 2023 | 136 | 1.290 |
Why?
| | Reflex, Startle | 9 | 2005 | 75 | 1.250 |
Why?
| | DNA Methylation | 9 | 2018 | 722 | 1.240 |
Why?
| | Alcoholic Intoxication | 5 | 2021 | 77 | 1.190 |
Why?
| | Central Nervous System Depressants | 10 | 2018 | 84 | 1.160 |
Why?
| | Middle Aged | 72 | 2026 | 36821 | 1.150 |
Why?
| | Gyrus Cinguli | 7 | 2017 | 99 | 1.090 |
Why?
| | Polymorphism, Single Nucleotide | 27 | 2018 | 2223 | 1.070 |
Why?
| | Cigarette Smoking | 3 | 2018 | 103 | 1.060 |
Why?
| | Narcotic Antagonists | 9 | 2019 | 210 | 1.050 |
Why?
| | Endocannabinoids | 2 | 2026 | 56 | 1.040 |
Why?
| | Receptors, Opioid, mu | 6 | 2018 | 67 | 1.020 |
Why?
| | Affect | 14 | 2024 | 323 | 1.020 |
Why?
| | Receptor, Cannabinoid, CB1 | 5 | 2012 | 39 | 1.000 |
Why?
| | Smoking Cessation | 10 | 2017 | 441 | 1.000 |
Why?
| | Taste | 5 | 2018 | 238 | 0.990 |
Why?
| | Alcoholic Beverages | 3 | 2017 | 32 | 0.970 |
Why?
| | Receptors, Nicotinic | 5 | 2014 | 328 | 0.970 |
Why?
| | Medical Marijuana | 4 | 2025 | 122 | 0.970 |
Why?
| | Motivation | 14 | 2015 | 615 | 0.970 |
Why?
| | Functional Neuroimaging | 9 | 2017 | 62 | 0.940 |
Why?
| | Impulsive Behavior | 9 | 2017 | 145 | 0.940 |
Why?
| | Psilocybin | 1 | 2026 | 5 | 0.930 |
Why?
| | Toll-Like Receptor 4 | 2 | 2018 | 277 | 0.930 |
Why?
| | Cognitive Neuroscience | 1 | 2025 | 9 | 0.900 |
Why?
| | Esthetics | 1 | 2025 | 50 | 0.880 |
Why?
| | Aging | 6 | 2026 | 1992 | 0.880 |
Why?
| | Eicosanoids | 1 | 2025 | 58 | 0.870 |
Why?
| | Amidohydrolases | 3 | 2009 | 31 | 0.860 |
Why?
| | Nicotine | 12 | 2019 | 336 | 0.860 |
Why?
| | Arousal | 6 | 2018 | 158 | 0.860 |
Why?
| | Nicotinic Agonists | 6 | 2017 | 135 | 0.860 |
Why?
| | Minisatellite Repeats | 9 | 2011 | 36 | 0.830 |
Why?
| | Taste Perception | 3 | 2015 | 31 | 0.800 |
Why?
| | DNA Copy Number Variations | 4 | 2012 | 190 | 0.790 |
Why?
| | Benzodiazepines | 6 | 2014 | 169 | 0.770 |
Why?
| | Phenotype | 12 | 2015 | 3216 | 0.730 |
Why?
| | Risk-Taking | 5 | 2021 | 325 | 0.730 |
Why?
| | Cerebral Cortex | 9 | 2022 | 483 | 0.710 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 481 | 0.680 |
Why?
| | Parietal Lobe | 4 | 2014 | 62 | 0.680 |
Why?
| | Cognition | 4 | 2025 | 1286 | 0.680 |
Why?
| | Irritable Bowel Syndrome | 2 | 2019 | 29 | 0.670 |
Why?
| | Public Health | 1 | 2026 | 577 | 0.640 |
Why?
| | Sensation Disorders | 1 | 2020 | 40 | 0.620 |
Why?
| | Adolescent | 43 | 2025 | 22825 | 0.620 |
Why?
| | Exercise | 8 | 2023 | 2219 | 0.610 |
Why?
| | Dopamine | 5 | 2013 | 295 | 0.610 |
Why?
| | Antipsychotic Agents | 3 | 2014 | 211 | 0.600 |
Why?
| | Psychotherapy, Brief | 2 | 2011 | 41 | 0.600 |
Why?
| | Food | 3 | 2017 | 150 | 0.600 |
Why?
| | Psychomotor Performance | 5 | 2013 | 326 | 0.590 |
Why?
| | Motor Activity | 3 | 2013 | 719 | 0.590 |
Why?
| | Genetic Variation | 5 | 2012 | 995 | 0.580 |
Why?
| | Models, Biological | 3 | 2015 | 1772 | 0.570 |
Why?
| | Exons | 2 | 2011 | 365 | 0.560 |
Why?
| | Diffusion Tensor Imaging | 3 | 2015 | 83 | 0.560 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2458 | 0.560 |
Why?
| | Plant Extracts | 1 | 2020 | 191 | 0.560 |
Why?
| | Self Report | 6 | 2021 | 887 | 0.550 |
Why?
| | Stress, Psychological | 5 | 2012 | 1174 | 0.540 |
Why?
| | Double-Blind Method | 16 | 2024 | 2080 | 0.530 |
Why?
| | Severity of Illness Index | 8 | 2018 | 2973 | 0.520 |
Why?
| | Receptors, GABA-A | 2 | 2009 | 138 | 0.510 |
Why?
| | Drinking | 1 | 2017 | 44 | 0.510 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 204 | 0.500 |
Why?
| | Exploratory Behavior | 4 | 2009 | 85 | 0.500 |
Why?
| | Decision Making | 4 | 2018 | 994 | 0.490 |
Why?
| | Saliva | 3 | 2019 | 252 | 0.480 |
Why?
| | Oxygen | 7 | 2013 | 998 | 0.480 |
Why?
| | Craving | 5 | 2023 | 42 | 0.480 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2013 | 48 | 0.470 |
Why?
| | Catechol O-Methyltransferase | 3 | 2011 | 20 | 0.470 |
Why?
| | Mental Disorders | 6 | 2025 | 1188 | 0.470 |
Why?
| | Corpus Striatum | 4 | 2017 | 181 | 0.460 |
Why?
| | Sex Characteristics | 6 | 2021 | 799 | 0.460 |
Why?
| | Heart Rate | 9 | 2018 | 860 | 0.450 |
Why?
| | Coronary Disease | 1 | 2018 | 382 | 0.440 |
Why?
| | Drug Users | 1 | 2015 | 43 | 0.440 |
Why?
| | Brain Injuries, Traumatic | 2 | 2021 | 462 | 0.440 |
Why?
| | Organ Size | 6 | 2025 | 465 | 0.440 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 773 | 0.430 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2015 | 155 | 0.430 |
Why?
| | Interview, Psychological | 2 | 2011 | 95 | 0.420 |
Why?
| | Anxiety | 3 | 2024 | 1149 | 0.410 |
Why?
| | Photic Stimulation | 5 | 2014 | 266 | 0.410 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 479 | 0.410 |
Why?
| | Cerebrum | 1 | 2013 | 7 | 0.410 |
Why?
| | Prefrontal Cortex | 3 | 2014 | 342 | 0.400 |
Why?
| | Retinal Dehydrogenase | 1 | 2013 | 29 | 0.400 |
Why?
| | Epigenesis, Genetic | 3 | 2013 | 708 | 0.390 |
Why?
| | Treatment Outcome | 15 | 2017 | 11947 | 0.380 |
Why?
| | Age Factors | 4 | 2026 | 3372 | 0.380 |
Why?
| | Chronic Pain | 1 | 2018 | 301 | 0.380 |
Why?
| | Sex Factors | 9 | 2025 | 2136 | 0.380 |
Why?
| | Body Weight | 1 | 2017 | 976 | 0.380 |
Why?
| | alpha-Synuclein | 1 | 2013 | 47 | 0.370 |
Why?
| | Biomedical Research | 1 | 2019 | 723 | 0.370 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2012 | 8 | 0.370 |
Why?
| | Pirenzepine | 2 | 2003 | 8 | 0.370 |
Why?
| | Models, Psychological | 6 | 2011 | 295 | 0.370 |
Why?
| | Genome-Wide Association Study | 3 | 2016 | 1496 | 0.360 |
Why?
| | Analysis of Variance | 12 | 2012 | 1302 | 0.360 |
Why?
| | Attention | 4 | 2020 | 464 | 0.350 |
Why?
| | Mouth | 2 | 2024 | 86 | 0.350 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2015 | 2030 | 0.340 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2011 | 48 | 0.340 |
Why?
| | Receptor, Muscarinic M2 | 1 | 2011 | 10 | 0.340 |
Why?
| | Cytokines | 3 | 2025 | 2086 | 0.340 |
Why?
| | Secondary Prevention | 2 | 2023 | 253 | 0.340 |
Why?
| | Personality | 2 | 2006 | 131 | 0.340 |
Why?
| | Cytidine Deaminase | 1 | 2011 | 59 | 0.340 |
Why?
| | Pharmacogenetics | 2 | 2010 | 176 | 0.330 |
Why?
| | Protons | 1 | 2011 | 96 | 0.330 |
Why?
| | Surveys and Questionnaires | 19 | 2013 | 6164 | 0.320 |
Why?
| | Extinction, Psychological | 1 | 2012 | 92 | 0.320 |
Why?
| | Limbic System | 2 | 2008 | 55 | 0.320 |
Why?
| | Intelligence | 1 | 2011 | 117 | 0.310 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 99 | 0.310 |
Why?
| | Gene Deletion | 1 | 2011 | 392 | 0.310 |
Why?
| | Gene Expression | 3 | 2010 | 1481 | 0.300 |
Why?
| | Alleles | 6 | 2011 | 909 | 0.300 |
Why?
| | Choice Behavior | 1 | 2011 | 181 | 0.300 |
Why?
| | Personality Inventory | 5 | 2011 | 134 | 0.300 |
Why?
| | Students | 3 | 2011 | 659 | 0.290 |
Why?
| | Text Messaging | 1 | 2012 | 189 | 0.290 |
Why?
| | Connectome | 3 | 2024 | 101 | 0.290 |
Why?
| | Genomics | 2 | 2012 | 839 | 0.290 |
Why?
| | Proteins | 2 | 2013 | 1024 | 0.290 |
Why?
| | Psychotherapy, Group | 1 | 2009 | 79 | 0.290 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1107 | 0.290 |
Why?
| | Avoidance Learning | 1 | 2009 | 63 | 0.280 |
Why?
| | Genetic Linkage | 1 | 2009 | 273 | 0.280 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2007 | 7 | 0.270 |
Why?
| | Breath Tests | 5 | 2009 | 77 | 0.270 |
Why?
| | Case-Control Studies | 11 | 2026 | 3660 | 0.270 |
Why?
| | Colorado | 5 | 2025 | 4591 | 0.270 |
Why?
| | Alcohols | 1 | 2007 | 26 | 0.260 |
Why?
| | Methylation | 2 | 2018 | 242 | 0.260 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2016 | 794 | 0.260 |
Why?
| | Counseling | 1 | 2011 | 407 | 0.260 |
Why?
| | Drug Resistance | 1 | 2007 | 145 | 0.250 |
Why?
| | Depression | 2 | 2024 | 1599 | 0.250 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 430 | 0.250 |
Why?
| | Obesity | 2 | 2018 | 3149 | 0.250 |
Why?
| | Acoustic Stimulation | 3 | 2013 | 334 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1776 | 0.250 |
Why?
| | Health Education | 1 | 2009 | 346 | 0.240 |
Why?
| | Hydrocortisone | 1 | 2008 | 300 | 0.240 |
Why?
| | Microbiota | 3 | 2024 | 736 | 0.230 |
Why?
| | Mental Health | 2 | 2025 | 813 | 0.230 |
Why?
| | Physical Fitness | 2 | 2020 | 209 | 0.230 |
Why?
| | Lipoxygenase | 1 | 2025 | 15 | 0.230 |
Why?
| | Biomarkers | 4 | 2025 | 4351 | 0.230 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 342 | 0.220 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2025 | 76 | 0.220 |
Why?
| | Genetic Association Studies | 5 | 2015 | 374 | 0.220 |
Why?
| | Homosexuality, Female | 1 | 2005 | 42 | 0.220 |
Why?
| | Program Evaluation | 1 | 2009 | 952 | 0.220 |
Why?
| | Self Concept | 1 | 2007 | 259 | 0.220 |
Why?
| | Helplessness, Learned | 1 | 2005 | 67 | 0.220 |
Why?
| | Adolescent Behavior | 3 | 2021 | 498 | 0.210 |
Why?
| | Body Mass Index | 4 | 2020 | 2470 | 0.210 |
Why?
| | CpG Islands | 2 | 2016 | 176 | 0.210 |
Why?
| | Patient-Centered Care | 1 | 2010 | 552 | 0.210 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2025 | 163 | 0.210 |
Why?
| | Social Perception | 1 | 2005 | 104 | 0.210 |
Why?
| | Genome, Human | 3 | 2012 | 426 | 0.200 |
Why?
| | Homosexuality, Male | 1 | 2005 | 234 | 0.200 |
Why?
| | Anti-Anxiety Agents | 1 | 2024 | 48 | 0.200 |
Why?
| | Dopamine Uptake Inhibitors | 2 | 2003 | 59 | 0.200 |
Why?
| | Tobacco Use | 1 | 2024 | 68 | 0.200 |
Why?
| | Alcohol Abstinence | 2 | 2014 | 13 | 0.200 |
Why?
| | Aspartic Acid | 3 | 2012 | 88 | 0.200 |
Why?
| | Schizophrenia | 2 | 2025 | 489 | 0.190 |
Why?
| | Nervous System Diseases | 1 | 2026 | 288 | 0.190 |
Why?
| | Habituation, Psychophysiologic | 1 | 2003 | 57 | 0.190 |
Why?
| | Chi-Square Distribution | 4 | 2012 | 528 | 0.180 |
Why?
| | Sequence Analysis, DNA | 2 | 2020 | 780 | 0.180 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2022 | 55 | 0.180 |
Why?
| | Cross-Over Studies | 2 | 2023 | 617 | 0.180 |
Why?
| | Phosphocreatine | 2 | 2012 | 44 | 0.180 |
Why?
| | Central Nervous System Stimulants | 2 | 2004 | 187 | 0.180 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2024 | 512 | 0.170 |
Why?
| | Creatine | 2 | 2012 | 63 | 0.170 |
Why?
| | Psychotic Disorders | 1 | 2024 | 199 | 0.170 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2021 | 44 | 0.170 |
Why?
| | Blood Pressure | 5 | 2018 | 1785 | 0.170 |
Why?
| | Individuality | 5 | 2011 | 149 | 0.170 |
Why?
| | Homozygote | 2 | 2012 | 199 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 537 | 0.170 |
Why?
| | Harm Reduction | 1 | 2021 | 49 | 0.160 |
Why?
| | Frontal Lobe | 2 | 2013 | 161 | 0.160 |
Why?
| | United States | 7 | 2026 | 16313 | 0.160 |
Why?
| | Cerebellar Cortex | 1 | 2021 | 20 | 0.160 |
Why?
| | Axons | 2 | 2013 | 206 | 0.160 |
Why?
| | Inflammation | 2 | 2025 | 2920 | 0.160 |
Why?
| | Hippocampus | 3 | 2021 | 989 | 0.160 |
Why?
| | Verbal Learning | 1 | 2020 | 73 | 0.150 |
Why?
| | Promoter Regions, Genetic | 2 | 2018 | 1253 | 0.150 |
Why?
| | Glutamic Acid | 2 | 2012 | 256 | 0.150 |
Why?
| | Dextroamphetamine | 1 | 1999 | 4 | 0.150 |
Why?
| | Support Vector Machine | 2 | 2018 | 34 | 0.150 |
Why?
| | DNA Mutational Analysis | 3 | 2012 | 414 | 0.150 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2420 | 0.150 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 2 | 2011 | 9 | 0.150 |
Why?
| | Alcohol Deterrents | 2 | 2018 | 26 | 0.150 |
Why?
| | Drug and Narcotic Control | 1 | 2019 | 24 | 0.150 |
Why?
| | Sexual Behavior | 2 | 2021 | 502 | 0.150 |
Why?
| | Sympathomimetics | 1 | 1999 | 19 | 0.150 |
Why?
| | Knowledge | 1 | 2019 | 61 | 0.150 |
Why?
| | Brain Chemistry | 2 | 2011 | 121 | 0.150 |
Why?
| | Comorbidity | 2 | 2018 | 1672 | 0.150 |
Why?
| | Amphetamine | 1 | 1999 | 38 | 0.140 |
Why?
| | Health Behavior | 3 | 2013 | 799 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 221 | 0.140 |
Why?
| | Juvenile Delinquency | 2 | 2013 | 95 | 0.140 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 593 | 0.140 |
Why?
| | Aged | 6 | 2026 | 26514 | 0.140 |
Why?
| | Pain | 1 | 2024 | 794 | 0.140 |
Why?
| | Neuropsychological Tests | 6 | 2018 | 1145 | 0.140 |
Why?
| | Environment | 2 | 2010 | 297 | 0.140 |
Why?
| | Cross-Sectional Studies | 5 | 2017 | 6011 | 0.140 |
Why?
| | Underage Drinking | 1 | 2018 | 22 | 0.130 |
Why?
| | Cocaine-Related Disorders | 2 | 2018 | 133 | 0.130 |
Why?
| | Mass Spectrometry | 1 | 2021 | 728 | 0.130 |
Why?
| | Placebo Effect | 1 | 2017 | 24 | 0.130 |
Why?
| | Dysbiosis | 1 | 2019 | 188 | 0.130 |
Why?
| | Speech | 2 | 2012 | 76 | 0.130 |
Why?
| | Tobacco Smoking | 1 | 2017 | 28 | 0.130 |
Why?
| | Benzazepines | 1 | 2017 | 35 | 0.130 |
Why?
| | Southwestern United States | 1 | 2017 | 93 | 0.130 |
Why?
| | Research Design | 3 | 2019 | 1157 | 0.130 |
Why?
| | Information Dissemination | 1 | 2019 | 227 | 0.130 |
Why?
| | Postural Balance | 1 | 2020 | 254 | 0.130 |
Why?
| | Pilot Projects | 5 | 2019 | 1912 | 0.120 |
Why?
| | Gene Frequency | 3 | 2008 | 498 | 0.120 |
Why?
| | Beverages | 1 | 2017 | 68 | 0.120 |
Why?
| | Interleukin-8 | 1 | 2018 | 269 | 0.120 |
Why?
| | Insulin Resistance | 1 | 2025 | 1253 | 0.120 |
Why?
| | Amygdala | 2 | 2021 | 203 | 0.120 |
Why?
| | Food Preferences | 1 | 2017 | 126 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2018 | 394 | 0.110 |
Why?
| | Reaction Time | 2 | 2011 | 438 | 0.110 |
Why?
| | Behavior | 2 | 2009 | 90 | 0.110 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 1 | 2015 | 20 | 0.110 |
Why?
| | Placebos | 3 | 2007 | 193 | 0.110 |
Why?
| | Exercise Therapy | 1 | 2020 | 489 | 0.110 |
Why?
| | Public Policy | 1 | 2015 | 81 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2013 | 5476 | 0.110 |
Why?
| | Models, Neurological | 2 | 2015 | 253 | 0.110 |
Why?
| | Radiography | 2 | 2015 | 862 | 0.110 |
Why?
| | Hypnotics and Sedatives | 2 | 2009 | 226 | 0.110 |
Why?
| | Legislation, Drug | 1 | 2015 | 73 | 0.110 |
Why?
| | Animals | 8 | 2019 | 38410 | 0.100 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 146 | 0.100 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 62 | 0.100 |
Why?
| | Signal Transduction | 3 | 2019 | 5272 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 769 | 0.100 |
Why?
| | Energy Intake | 1 | 2017 | 514 | 0.100 |
Why?
| | Drug Interactions | 2 | 2007 | 405 | 0.100 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 25 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 430 | 0.100 |
Why?
| | Interleukin-6 | 1 | 2018 | 784 | 0.100 |
Why?
| | Nerve Tissue Proteins | 2 | 2010 | 597 | 0.100 |
Why?
| | Nucleus Accumbens | 2 | 2021 | 136 | 0.100 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2013 | 30 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2013 | 60 | 0.100 |
Why?
| | Models, Genetic | 2 | 2007 | 536 | 0.100 |
Why?
| | Factor Analysis, Statistical | 2 | 2015 | 296 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 25 | 0.100 |
Why?
| | Sample Size | 1 | 2013 | 124 | 0.100 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2012 | 8 | 0.090 |
Why?
| | Norepinephrine | 1 | 2013 | 201 | 0.090 |
Why?
| | Receptors, Serotonin | 1 | 2012 | 34 | 0.090 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 434 | 0.090 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2008 | 201 | 0.090 |
Why?
| | Adaptation, Psychological | 2 | 2011 | 736 | 0.090 |
Why?
| | Body Temperature | 1 | 2013 | 229 | 0.090 |
Why?
| | Auditory Perception | 1 | 2013 | 115 | 0.090 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 88 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 110 | 0.090 |
Why?
| | Reproducibility of Results | 4 | 2023 | 3448 | 0.090 |
Why?
| | Lactic Acid | 1 | 2013 | 295 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 2133 | 0.090 |
Why?
| | Glycerylphosphorylcholine | 1 | 2011 | 5 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2014 | 3027 | 0.090 |
Why?
| | Inositol | 1 | 2011 | 25 | 0.090 |
Why?
| | Phosphorylcholine | 1 | 2011 | 19 | 0.090 |
Why?
| | Heterozygote | 1 | 2012 | 317 | 0.090 |
Why?
| | Choline | 1 | 2012 | 138 | 0.090 |
Why?
| | Linear Models | 2 | 2016 | 852 | 0.090 |
Why?
| | Visual Perception | 1 | 2013 | 184 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2013 | 185 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2011 | 47 | 0.090 |
Why?
| | Life Style | 2 | 2012 | 504 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.080 |
Why?
| | Association | 1 | 2011 | 12 | 0.080 |
Why?
| | Neuroanatomy | 2 | 2021 | 10 | 0.080 |
Why?
| | Genetic Markers | 1 | 2012 | 338 | 0.080 |
Why?
| | Carbon Monoxide | 3 | 2007 | 82 | 0.080 |
Why?
| | Risk | 2 | 2011 | 927 | 0.080 |
Why?
| | Prognosis | 2 | 2017 | 4383 | 0.080 |
Why?
| | Motivational Interviewing | 1 | 2012 | 122 | 0.080 |
Why?
| | Washington | 1 | 2011 | 157 | 0.080 |
Why?
| | Administration, Cutaneous | 2 | 2007 | 127 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 1996 | 606 | 0.080 |
Why?
| | Brain Diseases | 1 | 2011 | 158 | 0.080 |
Why?
| | Pregnanolone | 1 | 2010 | 34 | 0.080 |
Why?
| | Euphoria | 1 | 2009 | 2 | 0.080 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2010 | 195 | 0.080 |
Why?
| | Genetic Testing | 2 | 2015 | 493 | 0.080 |
Why?
| | Oxygen Consumption | 1 | 2013 | 721 | 0.080 |
Why?
| | New Mexico | 1 | 2009 | 105 | 0.080 |
Why?
| | Professional-Patient Relations | 1 | 2011 | 149 | 0.070 |
Why?
| | Temperance | 1 | 2009 | 20 | 0.070 |
Why?
| | Smoking Prevention | 2 | 2007 | 167 | 0.070 |
Why?
| | Social Class | 1 | 2011 | 266 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2011 | 627 | 0.070 |
Why?
| | Drug Design | 1 | 2010 | 177 | 0.070 |
Why?
| | Life Change Events | 2 | 2010 | 149 | 0.070 |
Why?
| | Presynaptic Terminals | 1 | 2009 | 89 | 0.070 |
Why?
| | Probability | 1 | 2009 | 309 | 0.070 |
Why?
| | Methamphetamine | 2 | 2019 | 75 | 0.070 |
Why?
| | Genetics, Behavioral | 1 | 2007 | 17 | 0.070 |
Why?
| | Brain Concussion | 1 | 2016 | 661 | 0.070 |
Why?
| | Gambling | 1 | 2007 | 29 | 0.060 |
Why?
| | DNA Primers | 1 | 2008 | 505 | 0.060 |
Why?
| | Time Factors | 4 | 2006 | 7173 | 0.060 |
Why?
| | Disruptive, Impulse Control, and Conduct Disorders | 1 | 2007 | 9 | 0.060 |
Why?
| | Neostriatum | 1 | 2007 | 37 | 0.060 |
Why?
| | Twins, Dizygotic | 1 | 2007 | 108 | 0.060 |
Why?
| | Prospective Studies | 3 | 2013 | 8164 | 0.060 |
Why?
| | Risk Factors | 4 | 2013 | 11017 | 0.060 |
Why?
| | Universities | 1 | 2009 | 453 | 0.060 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 617 | 0.060 |
Why?
| | Injections, Intravenous | 1 | 2007 | 198 | 0.060 |
Why?
| | Twins, Monozygotic | 1 | 2007 | 133 | 0.060 |
Why?
| | Physical Exertion | 2 | 2023 | 205 | 0.060 |
Why?
| | Siblings | 1 | 2007 | 197 | 0.060 |
Why?
| | Electromyography | 2 | 2000 | 419 | 0.060 |
Why?
| | Drinking Behavior | 1 | 2006 | 15 | 0.060 |
Why?
| | Synaptic Transmission | 1 | 2008 | 293 | 0.060 |
Why?
| | Self Efficacy | 1 | 2009 | 422 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Sensation | 1 | 2006 | 55 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 379 | 0.060 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2005 | 30 | 0.060 |
Why?
| | Heterosexuality | 1 | 2005 | 49 | 0.060 |
Why?
| | Social Values | 1 | 2005 | 41 | 0.060 |
Why?
| | Stereotyping | 1 | 2005 | 42 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2015 | 17560 | 0.060 |
Why?
| | DNA | 2 | 2010 | 1444 | 0.060 |
Why?
| | Bulimia | 1 | 2005 | 36 | 0.060 |
Why?
| | Health Promotion | 1 | 2012 | 792 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2009 | 718 | 0.050 |
Why?
| | Binding Sites | 2 | 2007 | 1319 | 0.050 |
Why?
| | Internal-External Control | 1 | 2005 | 74 | 0.050 |
Why?
| | Rivers | 1 | 2005 | 62 | 0.050 |
Why?
| | Synapses | 1 | 2009 | 448 | 0.050 |
Why?
| | Rain | 1 | 2005 | 39 | 0.050 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 75 | 0.050 |
Why?
| | Appetite | 1 | 2005 | 80 | 0.050 |
Why?
| | Cohort Studies | 3 | 2017 | 6099 | 0.050 |
Why?
| | Problem Solving | 1 | 2005 | 156 | 0.050 |
Why?
| | Interpersonal Relations | 1 | 2007 | 403 | 0.050 |
Why?
| | Ganglionic Stimulants | 1 | 2003 | 15 | 0.050 |
Why?
| | Pleasure | 1 | 2023 | 18 | 0.050 |
Why?
| | Cyproheptadine | 1 | 2003 | 3 | 0.050 |
Why?
| | Disasters | 1 | 2005 | 104 | 0.050 |
Why?
| | Rest | 1 | 2024 | 127 | 0.050 |
Why?
| | Serotonin Antagonists | 1 | 2003 | 32 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2009 | 781 | 0.050 |
Why?
| | Pregnancy | 2 | 1996 | 7274 | 0.050 |
Why?
| | Bupropion | 1 | 2003 | 48 | 0.050 |
Why?
| | Multimodal Imaging | 1 | 2024 | 138 | 0.050 |
Why?
| | Neural Pathways | 2 | 2016 | 320 | 0.050 |
Why?
| | Physical Stimulation | 1 | 2003 | 69 | 0.050 |
Why?
| | Anisotropy | 2 | 2013 | 78 | 0.050 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 154 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1868 | 0.050 |
Why?
| | Genetics, Population | 1 | 2004 | 226 | 0.050 |
Why?
| | Child Behavior | 1 | 2004 | 238 | 0.050 |
Why?
| | Attitude to Health | 1 | 2005 | 431 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2003 | 319 | 0.040 |
Why?
| | Emotions | 1 | 2007 | 583 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2005 | 563 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2021 | 26 | 0.040 |
Why?
| | Cognitive Dissonance | 1 | 2001 | 3 | 0.040 |
Why?
| | Running | 1 | 2023 | 234 | 0.040 |
Why?
| | Limit of Detection | 1 | 2021 | 92 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 90 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 161 | 0.040 |
Why?
| | Wechsler Scales | 2 | 2012 | 61 | 0.040 |
Why?
| | Boredom | 1 | 1999 | 2 | 0.040 |
Why?
| | Personality Tests | 1 | 1999 | 12 | 0.040 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 84 | 0.040 |
Why?
| | Psychophysiology | 1 | 1999 | 12 | 0.040 |
Why?
| | Neurons | 1 | 2009 | 1672 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1990 | 20 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2812 | 0.040 |
Why?
| | Conditioning, Classical | 1 | 2000 | 120 | 0.040 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 425 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2020 | 320 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2021 | 337 | 0.030 |
Why?
| | Thalamus | 2 | 2012 | 132 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2625 | 0.030 |
Why?
| | Amphetamine-Related Disorders | 1 | 2018 | 53 | 0.030 |
Why?
| | Blinking | 1 | 1997 | 11 | 0.030 |
Why?
| | Cocaine | 1 | 2019 | 162 | 0.030 |
Why?
| | Hyperkinesis | 1 | 2017 | 16 | 0.030 |
Why?
| | Self Administration | 1 | 2018 | 122 | 0.030 |
Why?
| | Pituitary-Adrenal System | 1 | 1999 | 166 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2018 | 63 | 0.030 |
Why?
| | Risk Assessment | 1 | 2007 | 3784 | 0.030 |
Why?
| | Association Learning | 1 | 2017 | 70 | 0.030 |
Why?
| | Electroencephalography | 1 | 2000 | 570 | 0.030 |
Why?
| | Central Nervous System Diseases | 1 | 1997 | 75 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1997 | 211 | 0.030 |
Why?
| | Volition | 1 | 1996 | 34 | 0.030 |
Why?
| | Computer Simulation | 2 | 2015 | 1018 | 0.030 |
Why?
| | Sampling Studies | 1 | 1996 | 98 | 0.030 |
Why?
| | Self-Assessment | 1 | 1996 | 75 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 1996 | 139 | 0.030 |
Why?
| | Maternal Behavior | 1 | 1996 | 84 | 0.030 |
Why?
| | Conduct Disorder | 1 | 2017 | 158 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 506 | 0.030 |
Why?
| | Hemodynamics | 1 | 2000 | 1127 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2015 | 173 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1997 | 242 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2015 | 153 | 0.030 |
Why?
| | Salivation | 2 | 2007 | 4 | 0.030 |
Why?
| | Athletic Performance | 1 | 2015 | 78 | 0.030 |
Why?
| | Event-Related Potentials, P300 | 1 | 2013 | 17 | 0.030 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 369 | 0.020 |
Why?
| | Carrier Proteins | 2 | 2004 | 731 | 0.020 |
Why?
| | Placenta | 2 | 1990 | 793 | 0.020 |
Why?
| | Chronic Disease | 1 | 1999 | 1844 | 0.020 |
Why?
| | Behavioral Symptoms | 1 | 2012 | 41 | 0.020 |
Why?
| | Evoked Potentials | 1 | 2013 | 132 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 60 | 0.020 |
Why?
| | Fornix, Brain | 1 | 2012 | 5 | 0.020 |
Why?
| | Spatial Analysis | 1 | 2012 | 21 | 0.020 |
Why?
| | Research | 1 | 2015 | 434 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2013 | 502 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1151 | 0.020 |
Why?
| | Water | 1 | 2015 | 452 | 0.020 |
Why?
| | Functional Laterality | 1 | 2012 | 241 | 0.020 |
Why?
| | Haplotypes | 1 | 2013 | 509 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2012 | 337 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2012 | 160 | 0.020 |
Why?
| | Luciferases | 1 | 2010 | 155 | 0.020 |
Why?
| | Methods | 1 | 2010 | 68 | 0.020 |
Why?
| | Cerebellum | 1 | 2012 | 227 | 0.020 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 78 | 0.020 |
Why?
| | Chromosomes | 1 | 2010 | 106 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 373 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 196 | 0.020 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2009 | 40 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 303 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 980 | 0.020 |
Why?
| | Transfection | 1 | 2010 | 930 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2009 | 232 | 0.020 |
Why?
| | Feedback, Psychological | 1 | 2007 | 24 | 0.020 |
Why?
| | Chewing Gum | 1 | 2007 | 8 | 0.020 |
Why?
| | Beer | 1 | 2007 | 13 | 0.020 |
Why?
| | Tablets | 1 | 2007 | 41 | 0.020 |
Why?
| | Capsules | 1 | 2007 | 42 | 0.020 |
Why?
| | Learning | 1 | 2011 | 446 | 0.020 |
Why?
| | Blood Platelets | 1 | 1990 | 381 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1550 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8430 | 0.010 |
Why?
| | Demography | 1 | 2007 | 283 | 0.010 |
Why?
| | Child | 2 | 2022 | 22979 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 1342 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2007 | 285 | 0.010 |
Why?
| | Body Temperature Regulation | 1 | 2007 | 106 | 0.010 |
Why?
| | Radar | 1 | 2005 | 2 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 895 | 0.010 |
Why?
| | Geographic Information Systems | 1 | 2005 | 45 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 297 | 0.010 |
Why?
| | Psychometrics | 1 | 2009 | 739 | 0.010 |
Why?
| | Geography | 1 | 2005 | 187 | 0.010 |
Why?
| | Cerebrovascular Circulation | 1 | 2007 | 293 | 0.010 |
Why?
| | Texas | 1 | 2005 | 278 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 874 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2009 | 625 | 0.010 |
Why?
| | Patient Compliance | 1 | 2008 | 591 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 406 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 390 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4169 | 0.010 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.010 |
Why?
| | Parent-Child Relations | 1 | 2004 | 272 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 499 | 0.010 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 2 | 1990 | 9 | 0.010 |
Why?
| | Societies, Medical | 1 | 2004 | 914 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4604 | 0.010 |
Why?
| | Databases, Factual | 1 | 2005 | 1504 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2005 | 693 | 0.010 |
Why?
| | Adenosine | 2 | 1990 | 255 | 0.010 |
Why?
| | Prevalence | 1 | 2004 | 2889 | 0.010 |
Why?
| | Immune System | 1 | 1997 | 181 | 0.010 |
Why?
| | Cell Membrane | 2 | 1990 | 711 | 0.010 |
Why?
| | Radioligand Assay | 1 | 1990 | 36 | 0.000 |
Why?
| | Tritium | 1 | 1990 | 67 | 0.000 |
Why?
| | 2-Chloroadenosine | 1 | 1989 | 3 | 0.000 |
Why?
| | Guanylyl Imidodiphosphate | 1 | 1989 | 2 | 0.000 |
Why?
| | Guanine Nucleotides | 1 | 1989 | 12 | 0.000 |
Why?
| | Vasodilator Agents | 1 | 1990 | 330 | 0.000 |
Why?
| | Kinetics | 1 | 1989 | 1569 | 0.000 |
Why?
|
|
Hutchison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|